Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ISA 2024 | Major unmet needs in amyloidosis: early diagnosis & addressing mechanisms of tissue damage

Taxiarchis Kourelis • 27 May 2024

ISA 2024

Amyloidosis Rare Diseases

In this video, Taxiarchis Kourelis, MD, Mayo Clinic, Rochester, MN, highlights key unmet needs in patients with amyloidosis, including the challenge of early diagnosis, and the need to better address and understand mechanisms of tissue damage. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding Pfizer

Feasibility study of computer vision for quantifying cardiac amyloid burden in biopsies

Feasibility study of computer vision for quantifying cardiac amyloid burden in biopsies

Taxiarchis Kourelis • 27 May 2024

Proteomic analyses of cardiac ATTR and AL amyloidosis: key findings and clinical implications

Proteomic analyses of cardiac ATTR and AL amyloidosis: key findings and clinical implications

Taxiarchis Kourelis • 27 May 2024

Related Videos

Promising therapies and approaches for systemic mastocytosis

Promising therapies and approaches for systemic mastocytosis

Deepti Radia • 12 Jun 2026

The hottest updates in MPNs from EHA 2026

The hottest updates in MPNs from EHA 2026

Prithviraj Bose • 11 Jun 2026

Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia

Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia

Maria Teresa Voso • 12 Jun 2026

Bezuclastinib in advanced systemic mastocytosis: the APEX trial

Bezuclastinib in advanced systemic mastocytosis: the APEX trial

Daniel DeAngelo • 11 Jun 2026